JP2011527317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527317A5 JP2011527317A5 JP2011517170A JP2011517170A JP2011527317A5 JP 2011527317 A5 JP2011527317 A5 JP 2011527317A5 JP 2011517170 A JP2011517170 A JP 2011517170A JP 2011517170 A JP2011517170 A JP 2011517170A JP 2011527317 A5 JP2011527317 A5 JP 2011527317A5
- Authority
- JP
- Japan
- Prior art keywords
- nogo
- use according
- antagonist
- administered
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010410 Nogo Proteins Human genes 0.000 claims 12
- 108010077641 Nogo Proteins Proteins 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 10
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 6
- 229960004181 riluzole Drugs 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7987408P | 2008-07-11 | 2008-07-11 | |
| US61/079,874 | 2008-07-11 | ||
| PCT/EP2009/058832 WO2010004031A2 (en) | 2008-07-11 | 2009-07-10 | Novel treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527317A JP2011527317A (ja) | 2011-10-27 |
| JP2011527317A5 true JP2011527317A5 (https=) | 2012-07-26 |
Family
ID=41395512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517170A Pending JP2011527317A (ja) | 2008-07-11 | 2009-07-10 | Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110268729A1 (https=) |
| EP (1) | EP2323691A2 (https=) |
| JP (1) | JP2011527317A (https=) |
| CA (1) | CA2730473A1 (https=) |
| WO (1) | WO2010004031A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| BR112014000742A2 (pt) * | 2011-07-13 | 2016-08-23 | Andrew A Wolff | terapia de combinação de als |
| AU2013285493A1 (en) | 2012-07-05 | 2015-01-22 | Glaxo Group Limited | Optimum dose regime of an anti-Nogo-A antibody in the treatment of amyotrophic lateral sclerosis |
| US20230399390A1 (en) * | 2019-10-24 | 2023-12-14 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
| WO2026041734A1 (en) * | 2024-08-22 | 2026-02-26 | Novago Therapeutics Ag | Methods for treating neurological disorders using anti-nogo-a antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753379B1 (fr) * | 1996-09-13 | 1998-10-30 | Rhone Poulenc Rorer Sa | Methode de traitement de la sclerose laterale amyotrophique |
| ES2346868T3 (es) * | 2002-08-10 | 2010-10-21 | Yale University | Antagonistas de receptor nogo. |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| EP2213684A3 (en) * | 2003-12-22 | 2011-05-18 | Glaxo Group Limited | Nogo-a antibodies for the treatment of Alzheimer disease |
| WO2006071469A2 (en) * | 2004-12-02 | 2006-07-06 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Modulation of the neuroendocrine system as a therapy for amyotrophic lateral sclerosis |
| HRP20120851T1 (hr) * | 2005-07-05 | 2012-11-30 | Glaxo Group Limited | Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba |
| CA2625341A1 (en) * | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
| GB0525662D0 (en) * | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| WO2007133731A2 (en) * | 2006-05-11 | 2007-11-22 | Avicena Group, Inc. | Creatine-ligand compounds and methods of use thereof |
-
2009
- 2009-07-10 JP JP2011517170A patent/JP2011527317A/ja active Pending
- 2009-07-10 US US13/003,657 patent/US20110268729A1/en not_active Abandoned
- 2009-07-10 EP EP09780440A patent/EP2323691A2/en not_active Withdrawn
- 2009-07-10 CA CA2730473A patent/CA2730473A1/en not_active Abandoned
- 2009-07-10 WO PCT/EP2009/058832 patent/WO2010004031A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2011527317A5 (https=) | ||
| JP2013520405A5 (https=) | ||
| JP2011522816A5 (https=) | ||
| JP2012520866A5 (https=) | ||
| JP2016512248A5 (https=) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2015517489A5 (https=) | ||
| JP2013542247A5 (https=) | ||
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| JP2012500004A5 (https=) | ||
| JP2011528333A5 (https=) | ||
| JP2010536849A5 (https=) | ||
| WO2009033755A3 (en) | Use of l-carnosine as a therapeutic agent | |
| JP2009537554A5 (https=) | ||
| JP2014513722A5 (https=) | ||
| WO2009046822A3 (en) | Use of the peptide ymdgtmsqv as a therapeutic agent | |
| JP2012517449A5 (https=) | ||
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2013502446A5 (https=) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2013541583A5 (https=) | ||
| JP2011046708A5 (https=) | ||
| JP2009541409A5 (https=) |